What is the Clinical Effectiveness of orphan drugs in Covid-19 patients when compared with Standard Care?
According to World Heath Organisation on 16th August 2021, there have beern 207,173,086 confirmed cases of Covid-19, including 4,361,996 deaths, reported to WHO. Where as in India 16th August 2021, there have been 32,225,513 confirmed cases of Covid-19 with 431,642 deaths,reported to WHO.
An Orphan Drug is a Pharmaceutical agent that is used to treat a rare medical condition. Orphan Drugs which are used in Covid-19 like Anakinra, Bevacizumab, Sargramostim, Nitazoxanide, Barcitinib.
The standard treatment like (Paracetamol, Naproxen, Ivermectin, hydroxychloroquine, steroids, budisonide, Anti-tussive, Anticoagulant, Anti-inflammatory /immunomodulatory therapy) fails in decreasing the viral load.
Primary Outcome: Mortality
Secondary Outcome: Orphan Drugs (Clinical Effectiveness)